secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001104659-24-066058
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Rigel shareholders approve reverse stock split (1:2–1:20) and 6.5M share increase for equity plan
--------------------------------------------------------------------------------

- Reverse stock split of common stock at ratio between 1:2 and 1:20 approved; 87.85M for, 42.50M against.
- Amended 2018 Equity Incentive Plan authorized additional 6.5M shares; 53.15M for, 48.24M against.
- Two directors elected: Brian L. Kotzin (78.45M for) and Gregg A. Lapointe (79.15M for) to terms until 2027.
- Advisory say-on-pay approved (74.74M for, 26.22M against); Ernst & Young ratified as auditor for FY2024.
- Adjournment proposal passed (83.11M for) to allow further solicitation if needed for reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924066058/0001104659-24-066058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924066058/tm2415798d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-066058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer